# Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma

> **NCT00403988** · PHASE2 · TERMINATED · sponsor: **American University of Beirut Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** vinorelbine

## Key facts

- **NCT ID:** NCT00403988
- **Lead sponsor:** American University of Beirut Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2007-12
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** The results of a same study design have shown low response with important side effects. Accordingly \& ethicly, the study has been stopped.
- **Last updated:** 2008-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403988, "Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00403988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*